Italy · Delayed Price · Currency is EUR Cytokinetics Statistics
Total Valuation
Cytokinetics has a market cap or net worth of EUR 6.60 billion. The enterprise value is 6.71 billion.
| Market Cap | 6.60B |
| Enterprise Value | 6.71B |
Important Dates
The next estimated earnings date is Wednesday, November 5, 2025.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 119.66M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +16.37% |
| Shares Change (QoQ) | +0.81% |
| Owned by Insiders (%) | 0.40% |
| Owned by Institutions (%) | 117.56% |
| Float | 119.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 90.36 |
| PB Ratio | -21.01 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -13.00 |
| EV / Sales | 90.31 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -17.97 |
Financial Position
The company has a current ratio of 6.76
| Current Ratio | 6.76 |
| Quick Ratio | 6.61 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.26 |
| Interest Coverage | -5.94 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -24.87% |
| Return on Invested Capital (ROIC) | -44.93% |
| Return on Capital Employed (ROCE) | -49.97% |
| Revenue Per Employee | 146,598 |
| Profits Per Employee | -1.04M |
| Employee Count | 498 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 45.29 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 68.78 |
| Average Volume (20 Days) | 11 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 6.25 |
Income Statement
In the last 12 months, Cytokinetics had revenue of EUR 73.01 million and -516.27 million in losses. Loss per share was -4.36.
| Revenue | 73.01M |
| Gross Profit | -259.62M |
| Operating Income | -465.75M |
| Pretax Income | -516.27M |
| Net Income | -516.27M |
| EBITDA | -457.77M |
| EBIT | -465.75M |
| Loss Per Share | -4.36 |
Balance Sheet
The company has 730.70 million in cash and 844.48 million in debt, giving a net cash position of -113.78 million.
| Cash & Cash Equivalents | 730.70M |
| Total Debt | 844.48M |
| Net Cash | -113.78M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -313.97M |
| Book Value Per Share | -2.63 |
| Working Capital | 643.29M |
Cash Flow
In the last 12 months, operating cash flow was -363.52 million and capital expenditures -10.05 million, giving a free cash flow of -373.57 million.
| Operating Cash Flow | -363.52M |
| Capital Expenditures | -10.05M |
| Free Cash Flow | -373.57M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -637.96% |
| Pretax Margin | -707.17% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Cytokinetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.37% |
| Shareholder Yield | -16.37% |
| Earnings Yield | -7.83% |
| FCF Yield | -5.66% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Cytokinetics has an Altman Z-Score of -1.99 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.99 |
| Piotroski F-Score | 3 |